{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:35:45Z","timestamp":1794242145584,"version":"4.9.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We conducted a multicenter prospective study on whether a comprehensive geriatric assessment (CGA) can predict the adverse events (AEs) of chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Patients aged\u2009\u2265\u200965\u00a0years with newly diagnosed DLBCL underwent a pretreatment baseline CGA consisting of six assessment tools: activities of daily living (ADL), instrumental ADL (IADL), mood, nutritional status, comorbidities, and cognitive function. An attending physician chose each patient\u2019s treatment but was blind to CGA results. Patients were grouped as \u201cdependent\u201d or \u201cindependent\u201d according to the CGA. The primary endpoint was to evaluate the association between chemotherapy-induced grade 3\u20134 toxicity and CGA. Of 86 patients, 78 completed the designated CGA. The median age was 79\u00a0years (65\u201389). Seventy-two patients were treated with a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP-like) regimen, and six were treated with low-toxicity regimens. Forty-one patients were classified as dependent and 37 as independent. In multivariate analysis, an impairment of IADL was independently associated with grade 3\u20134 leukopenia (odds ratio [OR] 0.63; 95% confidence interval [CI] 0.43\u20130.92, <jats:italic>p<\/jats:italic>\u2009=\u20090.017) and anemia (OR 0.67; 95% CI 0.50\u20130.90, <jats:italic>p<\/jats:italic>\u2009=\u20090.008). The presence of a comorbidity was also associated with grade 3\u20134 non-hematological toxicity (OR 2.17; 95% CI 1.37\u20133.43, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). The 4-year survival rate tended to be longer in the independent (72.7%) compared to dependent (56.9%) group. Overall, a CGA may be a useful tool for predicting serious AEs associated with chemotherapy in elderly patients with DLBCL.<\/jats:p>","DOI":"10.1038\/s41598-022-07164-w","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T11:02:48Z","timestamp":1645700568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Toshihiro","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Kiyomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"7164_CR1","unstructured":"The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan\u201919. Foundation for promotion of Cancer Research. https:\/\/ganjoho.jp\/data\/reg_stat\/statistics\/brochure\/2019\/cancer_statistics_2019.pdf (2020)."},{"key":"7164_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","volume":"87","author":"A Bosly","year":"2008","unstructured":"Bosly, A. et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann. Hematol. 87, 277\u2013283 (2008).","journal-title":"Ann. Hematol."},{"key":"7164_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235\u2013242 (2002).","journal-title":"N. Engl. J. Med."},{"key":"7164_CR4","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers, H. et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J. Clin. Oncol. 32, 2595\u20132603 (2014).","journal-title":"J. Clin. Oncol."},{"key":"7164_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.critrevonc.2005.06.003","volume":"55","author":"M Extermann","year":"2005","unstructured":"Extermann, M. et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit. Rev. Oncol. Hematol. 55, 241\u2013252 (2005).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"7164_CR6","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/0140-6736(93)92884-V","volume":"342","author":"AE Stuck","year":"1993","unstructured":"Stuck, A. E., Siu, A. L., Wieland, G. D., Adams, J. & Rubenstein, L. Z. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342, 1032\u20131036 (1993).","journal-title":"Lancet"},{"key":"7164_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3960\/jslrt.56.43","volume":"56","author":"Y Naito","year":"2016","unstructured":"Naito, Y., Sasaki, H., Takamatsu, Y., Kiyomi, F. & Tamura, K. Retrospective analysis of treatment outcomes and geriatric assessment in elderly malignant lymphoma patients. J. Clin. Exp. Hematop. 56, 43\u201349 (2016).","journal-title":"J. Clin. Exp. Hematop."},{"key":"7164_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 329, 987\u2013994 (1993).","journal-title":"N. Engl. J. Med."},{"key":"7164_CR9","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney, F. I. & Barthel, D. W. Functional evaluation: The Barthel Index. Md. State Med. J. 14, 61\u201365 (1965).","journal-title":"Md. State Med. J."},{"key":"7164_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton, M. P. & Brody, E. M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9, 179\u2013186 (1969).","journal-title":"Gerontologist"},{"key":"7164_CR11","doi-asserted-by":"crossref","unstructured":"Yesavage, J. A. et al. Development and validation of a geriatric depression screening scale: a preliminary report. J. Psychiatr. Res. 17, 37\u201349 (1982\u20131983).","DOI":"10.1016\/0022-3956(82)90033-4"},{"key":"7164_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000107592","volume":"24","author":"JW Jeong","year":"2007","unstructured":"Jeong, J. W. et al. A normative study of the Revised Hasegawa Dementia Scale: comparison of demographic influences between the Revised Hasegawa Dementia Scale and the Mini-Mental Status Examination. Dement. Geriatr. Cogn. Disord. 24, 288\u2013293 (2007).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"7164_CR13","doi-asserted-by":"crossref","unstructured":"Guigoz, Y, Lauque, S., Vellas, B. J. Identifying the elderly at risk for malnutrition. The Mini Nutritional Assessment. Clin. Geriatr. Med. 18, 737\u2013757 (2002).","DOI":"10.1016\/S0749-0690(02)00059-9"},{"key":"7164_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373\u2013383 (1987).","journal-title":"J. Chronic Dis."},{"key":"7164_CR15","doi-asserted-by":"crossref","unstructured":"Cheson B. D. et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 17, 1244. (1999). Erratum in: J. Clin. Oncol. 18, 2351 (2000).","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"7164_CR16","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","volume":"29","author":"A Hurria","year":"2011","unstructured":"Hurria, A. et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J. Clin. Oncol. 29, 3457\u20133465 (2011).","journal-title":"J. Clin. Oncol."},{"key":"7164_CR17","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1200\/JCO.1998.16.6.2065","volume":"16","author":"H G\u00f3mez","year":"1998","unstructured":"G\u00f3mez, H. et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin\u2019s lymphoma: results of a multivariate analysis. J. Clin. Oncol. 16, 2065\u20132069 (1998).","journal-title":"J. Clin. Oncol."},{"key":"7164_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/onco.13641","volume":"26","author":"K Oiwa","year":"2021","unstructured":"Oiwa, K. et al. Utility of the geriatric 8 for the prediction of therapy-related toxicity in older adults with diffuse large B-cell lymphoma. Oncologist. 26, 215\u2013223 (2021).","journal-title":"Oncologist."},{"key":"7164_CR19","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1002\/cncr.24490","volume":"115","author":"A Tucci","year":"2009","unstructured":"Tucci, A. et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 115, 4547\u20134553 (2009).","journal-title":"Cancer"},{"key":"7164_CR20","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/cncr.26646","volume":"118","author":"M Extermann","year":"2012","unstructured":"Extermann, M. et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age patients (CRASH) score. Cancer 118, 3377\u20133386 (2012).","journal-title":"Cancer"},{"key":"7164_CR21","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile, S. G. et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J. Clin. Oncol. 36, 2326\u20132347 (2018).","journal-title":"J. Clin. Oncol."},{"key":"7164_CR22","unstructured":"Japanese Society of Medical Oncology, Japan Society of Clinical Oncology. Chemotherapy and other drug therapies for older patients with cancer: JSMO-JSCO clinical practice guidelines. Available via https:\/\/www.jsmo.or.jp\/about\/doc\/guideline01_03.pdf (2019)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07164-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07164-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07164-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:49:47Z","timestamp":1669330187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07164-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7164"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-07164-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"15 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kazuo Tamura received research funding by the following companies: Sanofi KK, Chugai, Nippon Kayaku, ONO, Taiho, Taisho, and Yakult Honsha. The other authors declare that no conflicts of interest exist with regard to the present study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3124"}}